Loading
A phase 1/2 trial of ZG006 in neuroendocrine tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. is a phase 1/2 interventional study registered as NCT06440057 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 78 participants planned, started 2024-08-29 and due to reach its primary completion in 2026-05. Interventions recorded: ZG006.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/